

Pharmacology Exam 2

Marie Rishovd • Hanna Bentsen



First Edition
March 2024
Copyright StudyAid 2024

Authors

Marie Rishovd
Hanna Bentsen

Editors

Marie Rishovd
Hanna Bentsen
Anna Emilie Høifødt

Illustrators

Anna Edine Lind Jodalen
Marie Rishovd

Booklet Disclaimer

All rights reserved. No part of this book may be reproduced in any form on by an electronic or mechanical means, without permission from StudyAid.

Although the authors have made every effort to ensure the information in the booklet was correct at date of publishing, the authors do not assume and hereby disclaim any liability to any part for any information that is omitted or possible errors. The material is taken from a variety of academic sources as well as pharmacology lecturers, but are further incorporated and summarized in an original manner. It is important to note, the material has not been approved by professors of pharmacology.

All illustrations in the booklet are original. This booklet is made especially for students at the Jagiellonian University in Krakow by tutors in the StudyAid group (students at JUMC).

It is available as a PDF and is available for printing.

If you have any questions concerning copyrights of the booklet please contact studyaidkrk@gmail.com.

About StudyAid

StudyAid is a student organization at the Jagiellonian University in Krakow. Throughout the academic year we host seminars in the major theoretical subjects: anatomy, physiology, biochemistry, immunology, pathophysiology, supplementing the lectures provided by the university. We are a group of 25 tutors, who are students at JU, each with their own field of specialty. To make our seminars as useful and relevant as possible, we teach in an interactive manner often using drawings and diagrams to help students remember the concepts. In addition to most seminars we create booklets, on which the seminars are based to aid the students in following the presentations. If you have any questions, do not hesitate to contact StudyAid at www.studyaid.no, we are always happy to answer any questions you may have academically related or not.

Table of Contents

| | |
|---|-----------|
| Section 1 – Neurotransmitters of the CNS..... | 3 |
| 1.1 – General | 3 |
| 1.2 – GABA and Glutamate..... | 4 |
| 1.2 – Other Neurotransmitters | 6 |
| Section 2 – Drugs Affecting CNS..... | 7 |
| 2.1 – Sedative-Hypnotic and Anxiolytic Drugs | 7 |
| 2.2 – Local Anesthetics | 11 |
| 2.3 – General Anesthetics..... | 15 |
| 2.4 – Epilepsy..... | 20 |
| 2.5 – Psychosis..... | 25 |
| 2.6 Affective Disorders..... | 28 |
| 2.7 – Central Nervous System Stimulants..... | 33 |
| 2.8 - Test Yourself | 39 |
| Section 3 – Drugs for Neurodegenerative Diseases | 42 |
| 3.1 – General About Neurodegenerative Diseases | 42 |
| 3.2 – Parkinson Disease | 42 |
| 3.4 – Huntington Disease | 46 |
| 3.5 – Multiple Sclerosis (MS) | 47 |
| 3.6 – Amyotrophic Lateral Sclerosis (ALS)..... | 48 |
| 3.7 – Antispastic Drugs | 48 |
| 3.8 – Test Yourself: Neurodegenerative Diseases..... | 50 |
| Section 4 – Drugs for Abuse | 52 |
| 4.1 – Central Nervous System Depressants | 52 |
| 4.2 – Central Nervous System Stimulants..... | 54 |
| 4.3 – Other Psychoactive Drugs..... | 56 |
| 4.4 – Drugs for Treating Drug Dependence | 57 |
| 4.5 – Test yourself..... | 58 |

Section 1 – Neurotransmitters of the CNS

1.1 – General

1.2 – Amino Acid Transmitters

1.3 – Monoamine

1.4 – Other


1.1 – General

- Neurotransmitters are chemical messengers that transmits a signal from one nerve cell to another
- Criteria to be classified as a neurotransmitter
 1. Synthesis and Release: A neurotransmitter must be synthesized in a neuron and released from a presynaptic terminal
 2. Specific Responses: It should reproduce specific responses at the postsynaptic neurons, either excitatory or inhibitory
 3. Antagonist Blockage: The effect of the neurotransmitter should be dose-dependently blocked by antagonists
 4. Termination: After exerting its effect, a neurotransmitter must be reabsorbed, metabolized or inactivated to terminate the stimulation and prevent prolonged signaling

Neurotransmitters: Chemical messengers that transmits signals between neurons

Neuromodulators: Substances released by neurons that regulate the activity of neurotransmitters

1.1.1 – Types of Amino Acid Transmitters





- Most CNS drugs are exerted directly at the synapses.
- A synapse is the junction between two nerve cells, where a neural message is transmitted through the action of a neurotransmitter.
- Presynaptic is before the synapse, while postsynaptic is after the synapse.

- When neurotransmitters attach to their respective receptor, they will either cause an excitatory or inhibitory response;
 1. Excitatory is more likely to fire an action potential
 2. Inhibitory is less likely to fire an action potential
- Drugs act through different mechanisms;
 1. Presynaptically by altering the synthesis, storage, release, reuptake or metabolism of the neurotransmitter
 2. Postsynaptically mainly on receptors
 3. On the second messengers

1.2 – GABA and Glutamate

- GABA and glutamate are both amino acid neurotransmitters, amino acids which can transmit a nerve message across a synapse.
- Glutamate is the primary excitatory neurotransmitter, which allows for firing of action potentials.
- GABA is the primary inhibitory neurotransmitter, which inhibits firing of action potentials.

1.2.2 – Types of Amino Acid Transmitters

| | Gamma-aminobutyric acid (GABA) | | Glutamate | | |
|--------------------------|--|-------------------|--|------------------|---------|
| Importance | Can reduce neural transmission ¹ | | Important in learning and memory | | |
| Effect | Inhibitory | | Excitatory | | |
| Location | Brain and spinal cord | | All levels of CNS | | |
| Receptor |  | |  | | |
| Receptor subtypes | GABA _A | GABA _B | NMDA | AMPA | Kainate |
| Drugs | Benzodiazepines Barbiturates Zolpidem Alcohol | Baclofen | Phencyclidine Ketamine Memantine | Piracetam | |
| Most common clinical use | Sedation | Treat spasticity | Treat seizures | | |

¹The sedative effect of GABA is because of the ability to reduce neural transmission

²The NMDA receptor complex has a binding site for both glycine and glutamate

1.2 – Other Neurotransmitters

| Neurotransmitter | Type of neurotransmitter | Importance in CNS | Clinical significance in CNS | Location |
|-------------------------------------|-------------------------------|---|--|---|
| Glycine | Amino acid | Inhibitory action leading to suppressed neuronal firing | Strychine (poison) is an antagonist. No drugs in clinical use | Grey matter of spinal cord |
| Norepinephrine | Monoamine | Anxiety, learning, memory, mood, sensory, sleep | Target in some antidepressants | Neuronal tracts from locus ceruleus |
| Dopamine | Monoamine | Drug reinforcement, emesis, mood, motor coordination, olfaction | Target in some recreational use, treatment of parkinsonism | Neuronal tracts from ventral segmental area |
| Serotonin | Monoamine | Emotions, pain, appetite, sleep, mood, hallucinations | Target of action in most antidepressants | Neuronal tracts from raphe nuclei |
| Histamine | Monoamine | Modulate arousal, appetite, and memory | Drowsiness and sedation from some antihistamines | Widely distributed in brain |
| Acetylcholine | Cholinergic | Memory, arousal, and attention | Target in some drugs for Parkinson's and Alzheimer's disease | Spinal cord |
| Endorphins | Neuropeptide (opioid peptide) | Inhibit pain transmission, lower stress, improve mood | Drugs like morphine mimic its effect | Spinal cord and midbrain |
| Adenosine triphosphate (ATP) | Purine | Believed to augment the effect of other neurotransmitters | No clinical use | Whole CNS |
| Adenosine | Purine | Not well understood, but can alter the levels of cAMP | Caffeine inhibits adenosine receptors causing CNS stimulation | Whole CNS |

Section 2 – Drugs Affecting CNS

- 2.1 – Sedative-Hypnotic and Anxiolytic Drugs
- 2.2 – Local Anesthetics
- 2.3 – General Anesthetics
- 2.4 – Epilepsy
- 2.5 – Psychosis
- 2.6 – Affective Disorders
- 2.7 – CNS Stimulants
- 2.8 – Test Yourself

2.1 – Sedative-Hypnotic and Anxiolytic Drugs


- Sedative-hypnotic drugs are substances that can induce a calming or sleep-inducing effect.
- Anxiolytic drugs are substances that reduce or alleviate anxiety

2.1.1 – Benzodiazepines and Barbiturates

- Both benzodiazepines and barbiturates act on the GABA_A receptor
- Low dose of these drugs results in sedation and anxiety relief, while higher doses can result in hypnosis. However, the depth of the anesthesia is not enough to lose pain stimuli.
- Due to the fact that barbiturates can act on the chloride channel even in the absence of GABA, these drugs exhibit greater toxicity and also has a narrower therapeutic index.

SUFFIX
Benzodiazepines: -pam

SUFFIX
Barbiturates: -tal



| | Benzodiazepines | Barbiturates |
|---------------------------|--|---|
| Mechanism | Binds to the GABA _A receptor to potentiate inhibitory actions by GABA | |
| GABA _A subunit | Alpha 1 and gamma 2 | Beta 2 |
| Effect | Increases the <i>frequency</i> of chloride-channel opening | Increases the <i>duration</i> of chloride-channel opening |
| Other effects | Anterograde amnesia ¹ Muscle relaxation | Anterograde amnesia ¹ |
| Clinical use | First line acute anxiety states and panic attacks First line for all seizures, including status epilepticus Primary insomnia Anesthesia Bipolar disorders Muscle spasticity Alcohol withdrawal | Anxiety disorders Insomnia Induction of general anesthesia Seizure disorders |
| Toxicity | CNS depression Mild euphoric effect Hypotension Bradycardia or tachycardia | Hangover and daytime sedation Respiratory depression ² Coma ² Death ² |
| | Physical dependence Withdrawal syndrome | |
| Contraindications | Pregnancy | Pregnancy |
| Drug examples | Diazepam Lorazepam Clonazepam Flurazepam Midazolam | Phenobarbital Thiopental Pentobarbital |
| Antidote | Flumazenil | No antidote |

¹Will not remember what happens after the drug is administered, because they affect the ability to form new memories

²For benzodiazepines these symptoms only occur in combination with other CNS depressants like alcohol. This is because benzodiazepines work only in the presence of GABA, while barbiturates don't depend on its presence.

CLINICAL CORRELATION

Alcohol withdrawal

- Long-acting benzodiazepines like chlordiazepoxide and diazepam is used in the management of alcohol withdrawal
- This is because both alcohol and benzodiazepines act on the GABA receptor
- If the patient has hypokalemia, which is common in alcoholics, the hypokalemia should always be corrected before administering benzodiazepines

CLINICAL CORRELATION

Flumazenil

- An agitated patient with delirium receives Sobril (oxazepam) to calm down
- After a short time, the patient appears to be in a stuporous state
- Flumazenil is a selective competitive antagonist of the GABA receptor, and can therefore be used as an antidote in benzodiazepine toxicity

2.1.2 – Other Sedative-Hypnotic Drugs

- Non-benzodiazepine hypnotic drugs exert the same CNS effects as benzodiazepines, however they are less likely to cause tolerance and withdrawal syndrome
- These drugs can also be antagonized by flumazenil

| | Mechanism | Duration | Clinical use | Toxicities |
|--------------------|---|----------|-------------------------------|---|
| Zolpidem | Interacts with the alpha 1 subunit of GABA _A | Medium | To treat sleep onset insomnia | Similar effect as benzodiazepines but smaller |
| Zaleplon | | Short | | |
| Eszopiclone | | Long | | |

CLINICAL CORRELATION

Zopiclone (Imovane)

- Zopiclone is a drug commonly used to treat insomnia
- It is most commonly recommended for short-term treatment of insomnia
 - However, it is in some cases used nightly, for example in elderly patients

2.1.3 – Non-Sedating Anxiolytic Drugs

- Buspirone is an atypical sedative-hypnotic drug. It is a very selective anxiolytic drug, with very little CNS depressive effects

| | Mechanism | Clinical use | Toxicities |
|------------------|--|--|---|
| Buspirone | Partial agonist on the serotonin _{5-HT_{1A}} receptor | Due to the very slow onset of action, the drug is used for generalized anxiety disorders rather than panic attacks | Mild headache, dizziness, and nervousness. Low chance of tolerance or withdrawal syndrome with chronic use |

2.1.4 – Anxiolytics

- Anxiolytic drugs are drugs used to reduce symptoms of anxiety

| | Diphenylmethane derivatives | Diol derivartives |
|-----------------------|---|---|
| Mechanism | Inhibits activity of reticular formation ¹ | |
| Effects | Antihistaminic Spasmolytic Atropinic and antiemetic Weak local anesthesia | Strong hypnotic activity Muscle relaxation |
| Clinical use | Anxiolytic Antipsychotic Locomotion disease Hallucinations | Anxiolytic Sedation Antiepileptic |
| Toxicity ² | Sedation Allergic response Myelosuppression Slight dependency Seizures, ataxia, dizziness | Allergic response Myelosuppression Dependency/tolerance Euphoria or depression |
| Drugs | Hydroxyzine Azacyclonol Benxoctamine | Meprobamate Tybamate Phenoglicodol |

¹Reticular formation is a part of the brainstem that plays a crucial role in regulation of arousal, attention, and consciousness

²Toxicities in diphenylmethane derivatives are more common in hydroxyzine than the other drugs

2.1.5 – Other Drugs with Sedative, Hypnotic and/or Anxiolytic Action

- These drug classes are covered completely in pharmacology booklet 1.

| Drug class | Mechanism | Effect | Drug example |
|---|------------------------------|-----------------------------------|--|
| Antihistamines (1st generation) | Blocks H1 receptor in CNS | Sedative and hypnotic action | Diphenhydramine¹ Doxepin Hydroxyzine |
| Melatonin agonists | Activate melatonin receptors | Sedative and hypnotic action | Ramelteon |
| Beta blocker | Antagonize beta1 and beta2 | Anxiolytic No hypnotic action! | Propranolol² |

¹The active ingredient in many over-the-counter drugs to treat insomnia


²Ability to prevent tachycardia and other signs of sympathetic activation, can therefore be used to treat acute anxiety in for example stage fright

2.2 – Local Anesthetics

- Local anesthetics are drugs that temporarily block nerve signals in a specific area of the body, leading to loss of sensation in that localized region.
- Local anesthetics act on the voltage-dependent sodium channels by blocking them.
- The efficiency of local anesthetics depends on pKA, protein and lipid solubility.

SUFFIX

Local anesthetics: **-caine**




2.2.1 – Classes of Local Anesthetics

- Local anesthetics are divided into ester-bound and amide-bound, nowadays amide-bound is almost only used
- Local anesthetics exist in both ionized and non-ionized forms
 1. Non-ionized form: Penetrate the cell membrane
 2. Ionized form: Bind to and block the sodium channels

RULE

Amide-bound local anesthetics has two "i" in the name



- Epinephrine is a vasoconstrictive agent that can prolong the duration of local anesthetics if administered together. However, it should never be administered to tissues with end arteries as fingers, toes, ears, nose, and penis.

| | Amine-bound LA | Ester-bound LA |
|--------------------|---|---|
| Mechanism | Irreversible inhibition of the sodium channel | |
| Inactivation | Liver ¹ | Plasma |
| Stability | Stable ² | Unstable |
| Allergic reactions | Rare | Common |
| Drugs | Lidocaine Bupivacaine Ropivacaine Prilocaine | Cocaine Procaine Benzocaine Proparacaine |

¹Because amine-bound LA are metabolized in the liver it has a longer half-life and duration

²Increased stability make the drugs more resistant to e.g. heat

2.2.2 – Amine-Bound Drugs

| | Duration of action | Clinical use | Administration | Toxicity |
|--------------------|--------------------|---|--|--|
| Lidocaine | Short | EMLA cream Minor surgery Postherpetic neuralgia Ventricular arrhythmia | Topical Infiltration Nerve block Epidural Spinal | Rarely side effects CNS excitation |
| Prilocaine | Short | EMLA cream | Topical Infiltration | Methemoglobinemia ¹ |
| Mepivacaine | Short | | Infiltration Nerve block Epidural Spinal | |
| Bupivacaine | Medium | Most common LA used for obstetric epidural anesthesia Post-surgical pain | Infiltration Nerve block Epidural Spinal | Myocardial depression |
| Ropivacaine | Long | Post-surgical pain | Infiltration Nerve block Epidural | Less cardiac toxicity than bupivacaine |

¹Prilocaine is converted to a toxic metabolite than can cause methemoglobinemia if it accumulates, due to this it is only administered topical or by infiltration

CLINICAL CORRELATION

Lidocaine

- Lidocaine is the most commonly used local anesthetic
- Xylocaine is a brand name for lidocaine, which is commonly used for pain relief during insertion of nasogastric tubes or urinary catheterization
- The local anesthetics are in these cases administered as a topical gel

2.2.3 – Administration of Local Anesthetics

| | | Location | Clinical use |
|----------------------------|---------------------------|--|---|
| Topical | | Skin, mucous membranes, cornea | Pruritus Venipuncture or minor surgery ¹ Different disorders, e.g. hemorrhoids Ocular surgical procedures |
| Infiltration | | Injection into the subcutaneous tissue ² | Primarily minor surgical procedures Removal of foreign bodies Dental procedures |
| Regional anesthesia | Nerve block | Injection into a peripheral nerve or nerve plexus to block conductivity to an area of the body | Surgical procedures Ocular surgery |
| | Spinal³ | Injection into the subarachnoid space below where the spinal cord terminates (L2/L3) | Surgery |
| | Epidural | Injection into the lumbar or caudal epidural space | Labor and delivery |

¹Commonly EMLA, which is a liquid combination of lidocaine and prilocaine.

²Epinephrine is often used to decrease dose and increase duration of action.

³Spinal anesthesia takes a shorter time to perform, has a faster onset and a more efficient block than epidural anesthesia. However, it has a higher chance of hypotension and headache associated with CSF leakage.


CLINICAL CORRELATION

Epidural anesthesia

- Epidural anesthesia is a commonly used and very popular local anesthetic during physiological labor
- A catheter is put in place, and allows for periodic injections of the anesthesia
- This allows the patient to be relieved of pain but still feel the pressure of the labor
- Provides pain relief to the lower half of the body

2.2.4 – Side Effects of Local Anesthetics

- The most common cause of side effects with the use of local anesthetics is the unintended intravascular injection, which causes systemic toxicity.
- Side effects are listed below;




¹Applies more frequently to ester-type local anesthetics as they are metabolized to paraaminobenzoic acid (PABA), which can cause allergic effects

2.3 – General Anesthetics

- General anesthesia is a state of reversible unconsciousness, loss of sensation, and muscle relaxation induced for medical procedures.
- In general anesthesia all of the below should be present
 1. Unconsciousness
 2. Analgesia
 3. Loss of motor reflexes
 4. Amnesia
 5. Loss of autonomic recovery
- The anesthesia must be readily controllable, with fast induction and recovery. This cannot be achieved by one single drug; therefore, mixed anesthesia is indicated.

Stages of anesthesia




2.3.1 – Inhalational Anesthetics

- General anesthetics that are administered through inhalation rather than parenteral

I. Pharmacokinetics in inhalational anesthetics

- The inhalational anesthetics are both absorbed and eliminated through the lungs, this makes the pharmacokinetics rather different than other drugs
- Different factors determine the induction time and recovery time of the anesthetic
 1. Blood:gas partition coefficient
 2. Partial pressure of the anesthetic
 3. Ventilation rate



¹Determines the movement of the anesthetic from the lungs to other tissues

II. Potency of inhalational anesthetics

- The potency is best measured by MAC (Minimum Alveolar Concentration). The lower MAC is, the more potent is the anesthetic.
- MAC is the minimum concentration of anesthetic required to prevent movement in response to a noxious stimulus, in 50% of patients
- All anesthetic drugs have a MAC; however, they may vary among patients due to factors such as age and cardiovascular status

III. Drugs

- Inhalational drugs are divided into nonhalogenated and halogenated.
- These drugs act agonistically on the GABA_A receptor chloride channels, and therefore reducing excitability
- Inhalational drugs are the first choice for anesthesia in children, whereas sevoflurane is most common
- Inhalational drugs are rarely used for induction of anesthesia in adults, but can be used for maintenance of anesthesia

| | | Pharmacokinetics | Clinical use | Toxicity |
|------------------------|---------------------------------------|--|---|--|
| Non-halogenated | Nitrous oxide (NO₂) | Least potent Less reduction in consciousness More analgesia Mild euphoria | Minor surgery Dental procedures Balanced anaesthesia ¹ | Quite safe, no cardiovascular or pulmonary depression Megaloblastic anemia |
| Halogenated | Halothane | Rapid induction Rapid recovery Less analgesia Less muscle relaxation | Major surgical procedures Balanced anaesthesia ¹ | Halothane hepatitis Malignant hyperthermia ² Respiratory and cardiovascular depression Cardiac dysrhythmia |
| | Sevoflurane | | | |
| | Isoflurane | | | |
| | Desflurane | | | |

¹Incombination with other anesthetic agents, to provide better analgesia and lower concentration of the other drug. Nitrous oxide and halogenated drugs are commonly used in combination to get the best effect

²Malignant hyperthermia is a severe toxicity resulting in muscle fiber break down. Consequences includes rhabdomyolysis and renal failure. Anesthesia should be discontinued, and patient should be treated with dantrolene

CLINICAL CORRELATION

“Laughing gas”

- Nitrous oxide is also called “laughing gas”
 - This is due to its mild euphoric effect
- Nitrous oxide can in some cases be administered to pediatric patients to calm them down before stressful situations, like insertion of peripheral venous catheters
 - These euphoric effects have also resulted in the occurrence of some recreational use of the drug

2.3.3 – Parenteral Anesthetics

- Parenteral anesthetics are general anesthetics that are administered directly to the vein
- Use of parenteral anesthetics can be followed by an inhalational anesthetic to maintain the anesthesia

| | Mechanism | Advantages | Disadvantages | Drugs |
|------------------------|-----------------------------|---|--|--|
| Propofol | GABA _A agonist | Rapid onset of action, rapid elimination from the body | Cardiovascular and respiratory depression | Propofol |
| Barbiturates | | Rapid onset of action, more slowly eliminated | | Thiopental |
| Benzodiazepines | | Little cardiovascular or respiratory depression | Slower onset of action than thiopental | Midazolam |
| Etomidate | | Rapid onset of action and has the lowest cardiovascular effects | | Etomidate |
| Ketamine | Glutamate (NMDA) antagonist | Little effect on respiration Few side effects in children, commonly used in pediatric patients | Increase blood pressure Dissociative anesthesia ¹ Delirium and hallucinations during recovery | Ketamine |
| Opiates | Opioid agonists | Potent analgesic effect and no cardiovascular toxicity | Do not produce amnesia or complete loss of consciousness ² | Remifentanil Fentanyl |

¹When the patient appears dissociated from the environment without being unconscious, occurs when the drug is administered IV

²Because of this, opiates are combined with sedatives such as propofol to produce increase the level of consciousness


CLINICAL CORRELATION

General anesthesia

- In Norway, continuous infusion of propofol and remifentanil is the most common approach to general anesthesia due to its rapid action and recovery.
- Propofol provides sleep induction while remifentanil provides analgesia.
- You should always be aware of hypotension since it is the most common side effect of both drugs.
 - A multimodal approach (the use of more drugs simultaneously) is becoming more common to avoid side effects such as hypotension, to limit the use of opiates, and to provide better post-operative pain management.

2.3.4 – Antagonists of Adjuncts to Anesthesia

- Antagonists to the anesthetic's agent can be given during the recovery from general anesthesia
- When you use a neuromuscular blocker to provide complete muscle paralysis, the antagonist is required to wake up the patient properly. This is to ensure that the respiratory muscles will allow for spontaneous breathing.



2.3.5 – Commonly Used Drugs in General Anesthesia

| | |
|---|--|
| Induction | IV thiopentone, etomidate, midazolam, or propofol |
| Muscle paralysis | IV tubocurarine (NMB) |
| Maintenance of unconsciousness and analgesia | Inhalational anesthetic (NO ₂ + halogenated) ± IV analgesic agent (opiate) |
| Recovery | O ₂ , cholinesterase inhibitors, naloxone, flumazenil |

2.4 – Epilepsy

- Epilepsy is a neurological disorder of unprovoked seizures, whereas seizures are involuntary movements and thoughts caused by episodes of abnormal activity in the brain
- To diagnose epilepsy one of the two must be present
 1. At least 2 epileptic seizures
 2. 1 epileptic seizure if risk factors are present
- Epilepsy can be triggered by underlying disorders such as brain tumor, neurodegenerative diseases or head trauma

2.4.1 – Types of Epilepsy


- Generalized seizures: seizures affecting the whole brain and body
- Partial seizures: seizures affecting only a part of the brain and body
- Simple seizures: seizures where the consciousness is not lost
- Complex seizures: seizures where there is a loss of consciousness

| Generalized seizures | | Partial seizures | Status epilepticus |
|---|---|--|--|
| Tonic-clonic seizure “grand mal” | Absence seizure | | |
| 1. Tonic phase with muscle stiffness 2. Clonic phase with rhythmic jerking movements | Seizure with a sudden loss of consciousness and decreased muscle tone | Seizures that originate in only one hemisphere, causing localized symptoms | A medical emergency characterized by prolonged and continuous seizures |

2.4.1 – Antiepileptic Drugs (Anticonvulsants)

- Epilepsy is usually treated with a monotherapy, however if there is a lack of effect polytherapy can be considered

I. Mechanism of different anticonvulsants



¹This mechanism is important as it may terminate the seizure at an early stage by affecting the formation of the seizure foci to begin with.

II. Classification of anticonvulsants

| Classic anticonvulsants | Second generation anticonvulsants | Third generation anticonvulsants |
|--|--|---|
| Phenytoin Carbamazepine Oxcarbazepine Valproate Ethosuximide Phenobarbital Benzodiazepines | Lamotrigine Vigabatrine Gabapentine Felbamate Tiagabine Topiramate Levetiracetam Pregabalin Zonisamide | Lacosamide Rufinamide Stripentol Eslicarbazepine Retigabine Perampanel |

III. Drugs for partial seizures and generalized tonic-clonic seizures

- The first-line drugs for partial seizures and generalized tonic-clonic seizures are valproate, carbamazepine, and phenytoin
- Second-line drugs are phenobarbital and primidone. Phenobarbital is the oldest anticonvulsant that is used today.

| | Valproate | Carbamazepine | Phenytoin |
|------------------|--|---|---|
| Mechanism | Blocks voltage-gated sodium channels and T-type calcium channels Increase GABA synthesis May decrease glutamate synthesis | Blocks voltage-gated sodium channels | |
| Other actions | | Blocks norepinephrine reuptake | |
| Cyt P450 enzymes | Inhibits | Induction ¹ | Induction |
| Clinical use | Partial seizures All forms of generalized seizures ² Manic phase bipolar disorder Prophylaxis migraine | Partial seizures Tonic-clonic seizures First-line trigeminal neuralgia Bipolar disease | Partial seizures Tonic-clonic seizures |
| Toxicity | Relatively little sedation and drowsiness Nausea, GI complaints, weight gain Mild hepatic toxicity ³ Spina bifida and impaired cognitive development in offsprings | CNS depression GI reactions Aplastic anemia | Ataxia, diplopia, nystagmus, slurred speech Megaloblastic anemia Fetal hydantoin syndrome Osteomalacia Gingival hyperplasia Hirsutism Steven-Johnson syndrome Toxic epidermal necrosis |
| Related drugs | | Oxcarbazepine/Eslicarbazepine | Fosphenytoin |

¹A very potent inducer of cytochrome P450 enzymes, which results in acceleration of metabolism of many different drugs. Due to these drug-drug reactions, carbamazepine is rarely a first-choice drug now

²In difference to carbamazepine and phenytoin which can worsen absence seizures

³In rare cases, fatal hepatic toxicity has been observed. Therefore, all patients taking valproate should have their liver function monitored

II. Adjunct drugs for partial seizures

- Partial seizures are the most difficult seizures to control, therefore there are some newly developed adjunct drugs to assist the other drugs
- These drugs consist of mainly second-generation antiepileptic drugs

| | Mechanism | Clinical use | Toxicity |
|----------------------|---|---|--|
| Clorazepate | Enhances binding of GABA | Adjunct treatment for partial seizures Anxiety disorder | Drowsiness Lethargy Tolerance |
| Felbamate | Blocks glycine coactivation of NMDA receptors | Partial seizures that are refractory to treatment Children with LGS ¹ | Fatal aplastic anemia Acute hepatic failure |
| Tiagabine | GABA reuptake inhibitor | Adjunct treatment of partial seizures Generalized anxiety disorder Panic attacks | |
| Gabapentin | Increase release of GABA | All forms of partial seizures Postherpetic neuralgia Restless legs syndrome | Minimal at therapeutic doses |
| Levetiracetam | Not clear, but delay GABA neurotransmission | Adjunct treatment of partial seizures in children | Dizziness Nervousness |
| Pregabalin | GABA analog | Adjunct treatment of partial seizures Neuropathic pain Fibromyalgia Generalized anxiety disorders | |
| Lamotrigine | Blocks sodium and calcium channels, decrease glutamate | Effective adjunct drug to partial seizures All types of seizures LGS ¹ Manic phase bipolar disorder | Cerebellar dysfunction Drowsiness Rash Stevens-Johnson syndrome Aseptic meningitis |
| Vigabatrine | Irreversible inhibitor of GABA-T ³ | Adjunct treatment of partial seizures | Dizziness Drowsiness Psychosis |
| Zonisamide | Blocks sodium channels and reduces calcium ion flow | Adjunct treatment of partial seizures | Metabolic acidosis ³ |
| Topiramate | Not clear, blocks voltage-gated sodium channels GABA agonist Glutamate blockage | Adjunct treatment of partial seizures, and all other types of seizures | CNS side effects Steven Johnson syndrome Cleft palate in offspring |

¹Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy, with seizures beginning in early childhood

²GABA in the brain is irreversibly broken down by the enzyme GABA transaminase

³Serum bicarbonate levels should always be maintained, both before and after treatment

CLINICAL CORRELATION

Stevens-Johnson syndrome

- Stevens-Johnson syndrome is a potentially fatal form of erythema multiforme
- It is characterized by severe mucocutaneous and systemic lesions
- Patients starting to developing rash taking these drugs, should report to their doctor because it can develop into Steven-Johnson
- It is more common for patients taking a combination of lamotrigine and valproate

III. Drugs for generalized absence, myoclonic, or atonic seizures

- Drugs for generalized absence, myoclonic, or atonic seizures are treated with ethosuximide, clonazepam or valproate
- Lamotrigine is sometimes used as an adjunct to the other drugs

| | Ethosuximide | Clonazepam | Valproate |
|--------------|--|--|---|
| Mechanism | Inhibits T-type calcium channels | A benzodiazepine | Several mechanisms of action ² |
| Effect | Long half-life | | High efficiency |
| Clinical use | Drug of choice in absence seizures in children ¹ | Mainly in prolonged epileptic seizures | Absence, myoclonic, and atonic seizures |
| Toxicity | Little toxicity Dizziness, drowsiness, gastric distress, nausea | Sedation | Relatively little sedation GI effects |

¹Not very effective in adults or in other types of seizures. Valproate is usually used in these cases.

²Discussed more in an earlier chapter

IV. Drugs for status epilepticus

- Status epilepticus starts in stage 1, where continuous or multiple seizures are present.
- Seizures are associated with sensory, motor and cognitive impairment

| | | | |
|----------------|--|------------|---|
| Stage 1 | Early status epilepticus | 5 min | Benzodiazepines, diazepam is first line |
| Stage 2 | Established status epilepticus | 30-120 min | Intravenous antiepileptic drugs such as phenytoin, phenobarbital or valproate |
| Stage 3 | “Refractory” status epilepticus | 2-24 hours | Generalized anesthesia |
| Stage 4 | “Super-refractory” status epilepticus | >24 hours | Resistant to treatment |

2.5 – Psychosis

- A mental health condition in which impairment of the following results in decreased capacity to deal with the reality
 1. The thoughts
 2. Affective response
 3. Ability to distinguish between what is real and not
 4. Ability to relate to others and communicate
- Characteristics include impaired reality testing, hallucinations, and delusions

2.5.1 – Classification of Psychosis

| Primary psychosis | Secondary psychosis |
|---|--|
| When psychosis is the main disorder | When psychosis is caused by another issue |
| Schizophrenia Schizoaffective disorder Psychotic depression Some cases of bipolar disorder Delusional disorder Brief psychotic disorder Shared psychotic disorder | Medical conditions Substance intoxication or withdrawal Brain lesion |

2.5.2 – Symptoms

| Positive symptoms | Negative symptoms ¹ |
|---|--|
| Symptoms that the patient themselves associate with the disease. Presence of abnormal experiences. | Symptoms that the patient does not acknowledge to be a part of the disease. Absence or reduction of normal functioning. |
| Delusions Hallucinations Disorganized speech and behaviour | Affective flattening Asociality Anhedonia Avolition Blunted affect |

¹It is more difficult to treat negative symptoms than positive symptoms

2.5.3 – Antipsychotic Drugs


| | Typical antipsychotics (First generation) | Atypical antipsychotics (Second generation) |
|----------------------------|---|--|
| Main mechanism | D2 antagonism | Block D2 receptors Block serotonin receptors |
| Other effects ¹ | Block alpha-1 Block H1 Block M receptors | |
| Positive symptoms | Reduction | Reduction |
| Negative symptoms | Secondary negative symptoms ² | Some effect on reduction ² |
| Clinical use | Positive symptoms of schizophrenia Acute psychosis Tourette's syndrome Small dose for anxiety or insomnia | Schizophrenia Depression |
| Toxicity | Anticholinergic symptoms Orthostatic hypotension Sedation and weight gain Extrapyramidal symptoms ³ Torsade's de pointes Hyperprolactinemia Neuroleptic malignant syndrome Degenerative retinopathy | |
| | | Agranulocytosis ⁴ <u>Metabolic side effects</u> Hyperglycemia, diabetes Dyslipidemia, hypercholesterolemia |
| Drug examples | Chlorpromazine Phenothiazine Haloperidol Droperidol | Clozapine Quetiapine Risperidone Paliperidone |

¹Due to the drugs being non-selective there are a lot of side effects

²Because of underactivity of dopamine. The effect on serotonin in atypical antipsychotics are thought influence the negative symptoms

³More common in typical than atypical antipsychotics

⁴Most common with clozapine, and regular monitoring of blood cell counts are indicated



CLINICAL CORRELATION

Neuroleptic malignant syndrome (NMS)

- A patient with psychosis is treated with phenothiazines, after some time he experiences altered mental status, fever and autonomic instability
- For the doctor to diagnose the patient with NMS, at least two of the following must be present: diaphoresis, dysphagia, tremor, incontinence, altered consciousness, mutism, tachycardia, BP change, leukocytosis, muscle enzyme elevations
 - Severe rigidity and hyperthermia are common
 - The patient should immediately stop the neuroleptic drugs
 - Treatment include treating hyperthermia, starting intensive hydration and forced diuresis, and prescribing dantrolene to reduce rigidity

MNEUMONIC

Symptoms in NMS: **FALTER**

Fever
Arms
Leukocytosis
Tremors
Elevated CPK
Rigidity

2.6 Affective Disorders

- Group of disorders affecting the mood
- Include depression and hypomania or mania

2.6.1 – Classification of Affective Disorders


| Bipolar and related disorders | Depressive disorders |
|---|--|
| Bipolar I disorder Bipolar II disorder Cyclothymic disorder | Disruptive mood dysregulation disorder Major depressive disorder (MDD) Persistent depressive disorder (PDD) Premenstrual dysphoric disorder |
| Substance/medication-induced Caused by another medical condition | |

2.6.1 – Depression vs Hypomania

| | Depression | Hypomania |
|-----------------|---|---|
| Mood | Lowering | Persistent elevation |
| Self-perception | Reduced self-esteem and self-confidence, ideas of guilt and worthlessness | Marked feels of well-being, grandiose ideas, and overconfidence |
| Social | Reduced capacity of enjoyment (anhedonia), interest, energy and concentration | Increased sociability, talkativeness, over-familiarity |
| Activity | Psychomotor retardation | Increased energy and activity |
| Sleep | Disturbed | Decreased need |
| Libido | Loss of libido | Increased sexual energy |
| Appetite | Diminished | Diminished |

2.6.2 – Antidepressants

- Treatment of depression is complex and aims at different aspects
 1. Antidepressants
 2. Lifestyle
 3. Psychotherapy
 4. Social
- Remember that all drugs increasing levels of serotonin are at risk of developing serotonin syndrome
- Many antidepressive drugs act on the reuptake transporters. Inhibition of these transporters allows for increased levels of neurotransmitters in the synapse, and thereby increased neurotransmission



I. Tricyclic antidepressants (TCA)

- Block reuptake of norepinephrine (NET) and serotonin (SERT)
- Other actions of TCA include antagonistic activity on H1, M, Alpha 1, and sodium channel
- Since TCA interact with other receptor types it is associated with severe toxicities like seizures and cardiac dysrhythmia
- Toxicity can be lethal, and should be treated with sodium bicarbonate

| | Secondary amines | Tertiary amines |
|------------|---|---|
| Mechanism | NET > SERT | More SERT |
| Clinical | Depression OCD Diabetic neuropathy Anxiety disorders Neuropathic pain Migraine prophylaxis | |
| Toxicities | Less side effects | More sedation ¹ and side effects |
| Drugs | Nortriptyline Desipramine | Amitriptyline Clomipramine |

¹Often administered at bedtime

CLINICAL CORRELATION

Tricyclic antidepressants

- The choice of anti-depressants depends on the incidence of adverse effects
- For example, a patient which is very agitated or anxious, a TCA like amitriptyline that facilitates more sedation can be preferable

II. Selective serotonin reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake inhibitors (SNRI)

- SSRI has become the most commonly used drug for treatment of depression and some anxiety disorders

| | Selective Serotonin Reuptake Inhibitors (SSRI) | Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) |
|-----------------|--|---|
| Mechanism | Block SERT | Block NET and SERT |
| Compared to TCA | As effective but fewer side effects Increase alertness (taken in the morning) | No action on other receptors, thus fewer side effects |
| Effect | Take 1-2 months for maximum effect, not for acute treatment | |
| Clinical use | First-line depression First line OCD Bulimia nervosa Anorexia nervosa Panic disorder | Major depressive disorder Diabetic neuropathy Generalized anxiety disorder Fibromyalgia Menopausal flushing |
| Toxicities | Nervousness Dizziness Insomnia Male sexual dysfunction | |
| Drugs | Fluoxetine¹ (most common) Fluvoxamine Sertraline² | Duloxetine Venlafaxine |

¹Causes more drug interactions than other SSRIs

²Often preferred in elderly

CLINICAL CORRELATION

Prozac

- Prozac is a brand name for fluoxetine and is often referred to as the “happy pill” in daily life
- It is commonly used to treat depression

III. Other antidepressive drugs

- Most of the following drugs has partial activity on more receptors than are mentioned

| Drug class | Mechanism | Positive | Negative | Drug |
|--|---|---|---|----------------------|
| Serotonin Reuptake Inhibitors (SRI) | Antagonist at 5HT _{2A} | No anticholinergic effects Minimal cardiac conduction | Sedation ¹ Orthostatic hypotension | Trazodone |
| Serotonin modulator and stimulator (SMS) | Selective SERT | Very safe in comorbidities like renal and hepatic insufficiency | | Vortioxetine |
| Noradrenaline reuptake inhibitors (NRI) | Inhibit reuptake at NET | | The least effective antidepressant | Reboxetine |
| Noradrenaline dopamine reuptake inhibitors (NDRI) | Inhibit reuptake at DAT, NET, SERT | Few anticholinergic side effects Little sedation Rarely cardiovascular effects or sexual dysfunction ² | Agitation Insomnia Nausea Weight loss | Bupropion |
| Atypical antidepressants | Blocks 5HT-2 and 5HT-3 receptors Increase central NE | Better tolerated and fewer side effect than TCA | Elevated hepatic enzymes Agranulocytosis | Mirtazapine |
| Monoamine oxidase inhibitors (MAO-I) | Irreversible inhibition of monoamine oxidase (MAO-A) ³ | Alternative therapy in failure of response | Many drug interactions Hypertensive crisis (Avoid tyramine containing food) ⁴ | Isocarboxazid |

¹Used when sleep disturbances are one of the worst symptoms

²Can be beneficial for patients suffering from sexual dysfunction caused by the other drugs

³Enzyme responsible for degradation of norepinephrine, dopamine, and serotonin


⁴Can increase the risk of hypertensive crisis

2.6.3 - Mood Stabilizing Drugs

- Drugs that aim to reduce mood swings in patients with bipolar disorder
- Lithium is the most commonly used mood stabilizing drug

I. Lithium

- Lithium is a drug that reduces both manic and depressive symptoms, but it is more effective in the manic phase

| | Lithium | |
|-------------------|---|--|
| Mechanism | <p>Not well understood, but believed to suppress formation of second messengers and inositol triphosphate</p>  <pre> graph LR A[Reduce formation of IP3] --> B[Reduce neuronal response to serotonin and norepinephrine] B --> C[Suppress formation of second messengers] C --> D[Influence neurosignaling] </pre> | |
| Effect | Stabilizing from “above” Calming effect in manic patients, and mild antidepressive effect | |
| Onset | Onset is days or weeks, and adjunct therapy is indicated until maximum response to lithium | |
| Clinical use | Bipolar disorders, especially with recurrent manic episodes Anti-suicidal effect Enhance effectiveness of antidepressants | |
| Toxicity | Narrow therapeutic index ¹ | |
| | <u>Lithium overdose (increased levels)</u> First symptom: nausea and vomiting Neurotoxicity and cardiotoxicity | <u>Side effects (therapeutic levels)</u> Drowsiness Weight gain Hand tremor Polyuria Hypothyroidism |
| Interactions | NSAIDS and diuretics decrease lithium clearance | |
| Contraindications | Teratogenic, can cause Epstein’s anomaly | |

¹There is a low margin of toxicity, and serum concentration should always be monitored

II. Other mood-stabilizing drugs

- Some drugs are thought to have an equal or greater efficiency and to be better tolerated than lithium
- These drugs are covered more thoroughly in an earlier chapter.

| | Mechanism | Indications in mood-stabilizing | Stabilizer |
|----------------------|---|---------------------------------|--------------|
| Carbamazepine | Inhibits sodium channels | Second choice stabilizers | From “above” |
| Valproate | Inhibits sodium channels and enhance GABA | Manic episodes | From “above” |
| Lamotrigine | Inhibits sodium channels and decrease glutamate release | Depressive episodes | From “below” |


2.7 – Central Nervous System Stimulants

- Stimulants are substances that enhance neural activity, increasing attention, alertness, and energy level. They usually work by increasing release or blocking reuptake of neurotransmitters, e.g. dopamine or norepinephrine, in the brain.

2.7.1 – Sympathomimetics


- Used to treat ADHD, narcolepsy, obstructive sleep apnea and shift work sleep disorder.

I. Amphetamine - see also 4.2.1



II. Sympathomimetics increasing catecholamines

- Substances that produce effects similar to the sympathetic nervous system.



¹ Less irritability, anxiety and anorexia than amphetamine.


² Not approved for ADHD treatment in children.

III. Other sympathomimetics

| | Mechanism | Clinical | Risk factors |
|---|--|--|---|
| Atomoxetine | Norepinephrine reuptake inhibitor | Treat ADHD | - Cardiovascular risks - Decrease weight gain and growth in children - Potential for drug abuse |
| Phentermine (amphetamine derivative) | Sympathomimetic mechanisms stimulating satiety center. | Appetite suppressant (obesity treatment) | |

2.7.2– Opioids

- Opioids interact with opioid receptors in the brain and the body to relieve pain and produce feelings of euphoria and relaxation. They include substances like morphine, oxycodone, and fentanyl.



I. Opioids and pain


- Pain is an uncomfortable and emotional experience alerting an individual to actual or potential tissue damage. Analgesics are a symptomatic treatment of pain.
- Opioid analgesics act in the spinal cord and brain to inhibit the neurotransmission of pain.
- Opioid receptors: μ (mu), δ (delta) and κ (kappa); mostly μ clinically

II. Classification

- Strong agonists: well tolerated, relieve severe pain.
- Moderate agonists: submaximal doses used for moderate/mild pain + NSAIDs.
- Mixed agonist-antagonist: varying combinations lead to various degree of affinity.
- Antagonists: no analgesic effects

III. Tolerance

- Chronic or long-term administration of opioids will decrease the pharmacological effects, leading to increased doses necessary for the same analgesic



CLINICAL CORRELATION

Opioid allergy

- An allergy to opioids is not uncommon. It can present in various ways, e.g. skin reactions, respiratory symptoms, GI symptoms, swelling or cardiovascular symptoms.
- Usually, a patient who is allergic to one opioid can use an **opioid from a different chemical class**.
- E.g. fentanyl could probably be used in a patient allergic to codeine.

2.7.3 – Opioid Agonists

I. Strong opioids

- Equivalent analgesic effects, but differ in pharmacokinetic properties, adverse effects and uses.
- Opioid agonists have respiratory depression and sedation as adverse effects.

| | Route of administration | Duration | Active metabolite | Clinical (pain related to...) | Adverse effects |
|----------------------|---|--------------------------|--|--|------------------------|
| Morphine | Oral (larger doses), Parenteral | 4h | 6-glucuronide | Trauma, MI, cancer PULMONARY EDEMA? | Nausea Constipation |
| Fentanyl | Parenteral, transdermal, sublingual, buccal | 1h | No | Chronic pain, augment anesthesia | Truncal rigidity |
| Remifentanyl | IV | 4 min (ultrarapid onset) | No | Anesthesia (short procedures) | |
| Meperidine | Oral, Parenteral | 3h | Normeperidine | Obstetric or postsurgical | Seizures, tremor |
| Methadone | Oral, Parenteral | 8h | No | Chronic, treat opioid addiction | |
| Oxycodone | Oral | 4h | No | Acute and chronic | |
| Hydromorphone | IM, IV, subcutaneous, rectal, oral. | 4h | 3-glucuronide (a little 6-glucuronide) | Acute and chronic | |

II. Moderate opioid agonists

- Used at submaximal doses in combination with an NSAID.

| | Mechanism | Clinical | Toxicities |
|--------------------|--------------------|--|---|
| Codeine | μ-receptor agonist | Always combined with NSAIDs: - mild to moderate pain - diarrhea - cough (codeine) | (less than the strong opioids) - Respiratory depression - Constipation - Addiction liability |
| Hydrocodone | | | |

III. Other opioid agonists

| | Mechanism | Clinical | Toxicities |
|-----------------------------|--|--|--|
| Tramadol | μ-receptor agonist + inhibits reuptake of serotonin and norepinephrine | Used orally to manage chronic pain Only partially inhibited by naloxone | Minimal opioid toxicities - Increased seizure risk (in combination with antidepressants) - increased risk of suicidality |
| Tapentadol | μ-receptor agonist + Inhibits reuptake of norepinephrine | | |
| Dextromethorphan | weak μ-receptor agonist + NMDA blocker | Anti-cough medication | Toxic in overdose |
| Diphenoxylate | μ-receptor agonist in GI smooth muscle | Oral administration Treatment of diarrhea | Chronic ingestions: -> anticholinergic side effects (diphenoxylate) |
| Loperamide (Imodium) | | <i>Do not use in diarrhea with fever!</i> | -> cardiac toxicity (loperamide) |

CLINICAL CORRELATION

Loperamide/Imodium

- To be allowed to go scuba diving, one should not be sick, however, whilst traveling people might experience a stomach bug and wish to avoid stomach issues during diving.
- This is not recommended, as Loperamide/Imodium **might not work underwater.**
- Should also be avoided as it can have sedative effects, therefore should not be used whilst diving.

IV. Mixed opioid agonist-antagonist

- Agonist/antagonist activity at μ -receptors + agonist/antagonist activity at κ -receptors.

| | Buprenorphine | Butorphanol | Nalbuphine | Pentazocine |
|-----------------|--|---|---|---|
| Route of admin. | Sublingual | Parenterally (+nasal) | Parenterally | IM (IV + subcut.+ oral) |
| Clinical | Sedation | Postoperative pain + migraine induced pain | Moderate pain | Sedation Child delivery |
| Receptors | κ - + δ - antagonist μ -partial agonist | κ -agonist μ -antagonist/agonist (weak) | κ -agonist μ -antagonist (weak) | κ -agonist μ -antagonist (weak) |

2.7.4 – Opioid Antagonists

- Naltrexone and naloxone are competitive opioid receptor antagonists.
- Used for treatment of opioid overdose, alcohol and opioid dependence, and opioid-induced constipation.

| | Naloxone | Naltrexone |
|-------------------------|--|--|
| Mechanism | Opioid receptor antagonists | |
| Duration | 1-2h | 24-36h (can also be used long-term) |
| Route of administration | IV Nasal spray | Oral |
| Clinical | - Opioid overdose - Opioid maintenance therapy - Opioid-induced constipation | - Alcohol and opioid dependence - Opioid-induced constipation |

2.8 - Test Yourself

1. What is the antidote to benzodiazepines?

- a) Naloxone
- b) Flumazenil
- c) Tramadol
- d) Aspirin

2. Which drug is not used in the treatment of generalized tonic-clonic seizures?

- a) Valproate
- b) Carbamazepine
- c) Phenytoin
- d) Pregabalin

3. Which local anesthesia can only be used for topical anesthesia?

- a) Bupivacaine
- b) Lidocaine
- c) Prilocaine
- d) Cocaine

4. How is the potency of inhalational anesthetics measured?

5. Describe the actions of anticonvulsant drugs?

6. What is the first-line drug for all seizures?

- a) Phenytoin
- b) Barbiturates
- c) Benzodiazepines
- e) Valproate

7. What is the first-line drug for depression?

- a) SSRI
- b) Clozapine
- c) TCA
- d) Valproate

8. Which phase of bipolar disorder is treated with lithium?

- a) Manic phase
- b) Depressive phase


9. Which anesthetic can cause dissociative anesthesia?

- a) Propofol
- b) Etomidate
- c) Barbiturate
- d) Ketamine

10. Drag a line between the drug class and the suffix

| | |
|-------------------|--------|
| Benzodiazepines | -Pam |
| Barbiturates | -Caine |
| Local anesthetics | -Tal |

11) Fill in the correct opioid classification.



12) A patient presents to the doctor experiencing itching, hives and swelling after ingestion an opioid for pain relief. Do the patient have to find another analgesic than opioids to treat their chronic pain?

13) Match the duration of action with the correct strong opioid?

- | | |
|-----------------|----------|
| 1) Morphine | a) 4h |
| 2) Remifentanyl | b) 1h |
| 3) Methadone | c) 4 min |
| 4) Fentanyl | d) 8h |

14) What other analgesic is moderate opioid agonists usually combined with?

- a) Paracetamol
- b) NSAIDs
- c) Tramadol
- d) Local anesthetics

15) Which of the following mixed opioid agonist-antagonists IS NOT an κ -receptor agonist?

- a) Buprenorphine
- b) Butorphanol
- c) Nalbuphine
- d) Pentazocine

16) Why do first-responders use naloxone instead of naltrexone when treating an opioid overdose?

- a) Naloxone can be administered as a nasal spray.
- b) Naloxone has a short half-life and may need repeated doses.
- c) Naltrexone has high oral bioavailability and is used long-term to treat opioid addicts.
- d) All of the above

Section 3 – Drugs for Neurodegenerative Diseases

3.1– General about Neurodegenerative Diseases

3.2 – Parkinson Disease

3.3 – Alzheimer Disease

3.4 – Huntington Disease

3.5 – Multiple Sclerosis

3.6 – Amyotrophic Lateral Sclerosis (ALS)

3.7 – Antispastic Drugs

3.8 – Test Yourself

3.1 – General About Neurodegenerative Diseases


- Neurodegenerative diseases are characterized by loss of function in groups of neurons in different parts of the CNS.
- They are pathological, progressive, and with unknown etiology. However, they are suggested to be caused by environmental factors, autoimmunity, or inheritance.
- There is limited research on neurodegenerative diseases, however, there are newly introduced drugs on both Parkinson and Alzheimer disease.
- Drugs from different chemical classes are used to treat different symptoms of the diseases.

3.2 – Parkinson Disease

- Resting tremor, rigidity, bradykinesia, gait problems and postural instability are typical symptoms of parkinsonism.
- This results from extensive degeneration of dopaminergic neurons in substantia nigra, which leads to loss of dopamine production in the brain.

3.2.1– Drugs that Increase Dopamine Levels

- Increasing the dopamine levels will not prevent or stop the progression of the disease, but it will help avert the symptoms.
- Dopamine itself cannot cross the blood-brain barrier to a significant extent by itself and can therefore not be used.




3.2.2 – Dopamine Receptor Agonists

- Activate dopamine receptors directly.
- Useful in advanced cases of Parkinson’s (almost no neurons left) as they do not need a functional dopaminergic neuron to produce an effect.

| | D ₁ | D ₂ | D ₃ |
|---|---------------------------|----------------|----------------|
| Apomorphine | Dopamine receptor agonist | | |
| Bromocriptine (Parlodel)¹ | Antagonist | Agonist | - |
| Pramipexole | - | Agonist | Agonist |
| Ropinirole | - | Agonist | - |
| Rotigotine | - | Agonist | Agonist |

¹ Ergot alkaloid (same class as LSD)




¹ A formulation can be used for diabetes 2

² For acute intermittent hypomobility in PD

³ Pimavanserin (antipsychotic) is used for treating the hallucinations associated with PD or the treatment of PD.

3.2.3 – Cholinergic Receptor Antagonists (antimuscarinic agents)

- Dopaminergic drugs are generally more effective, but antimuscarinic agents may be helpful in combination.
- Reduce tremor in PD.




3.3 – Alzheimer Disease

- Neurodegenerative disease of unknown etiology, characterized by progressive cognitive impairment (especially memory and cognition), severe disability, and dependence.

3.3.1 – Central Acetylcholinesterase Inhibitors

- Used to improve the cholinergic neurotransmission.
- Does not change course of disease, only slows the cognitive deterioration.
- Mechanism of AChE is covered in pharmacology booklet 1.



3.3.2 – Other Agents

| | Mechanism | Clinical | Toxicities |
|--------------------|---|--|---|
| Caprylidene | Metabolized into ketone bodies -> replace depleted glucose levels | Dietary supplement Age-associated memory impairment and AD. | - diarrhea - other GI symptoms |
| Memantine | Noncompetitive NMDA-receptor antagonist | Dementia of AD | - confusion - dizziness + headache - drowsiness - insomnia |

CLINICAL CORRELATION


Pseudobulbar affect

- **Dextromethorphan** is a drug with significant antitussive effects
- Combined with **quinidine** (antiarrhythmic), dextromethorphan can be used in the treatment of **pseudobulbar affect**.
- Pseudobulbar affect includes outbursts of uncontrollable crying or laughter in inappropriate settings, often seen in AD, MS and ALS.
 - Dextromethorphan inhibits NMDA receptors that are involved in regulating emotional expression. Quinidine inhibits the CYP2D6 enzyme which metabolizes dextromethorphan, resulting in an increase of the drug.

3.4 – Huntington Disease

- An autosomal dominant disorder with involuntary “dancing” movements (chorea) and often psychosis or dementia.
- The GABA function in the brain is diminished and the dopaminergic functions enhanced.

3.4.1 – Drugs



3.4.2 – Adverse effects

| | Adverse effects |
|--------------------------|---|
| Haloperidol | Extrapyramidal dysfunction. |
| Tetrabenazine | Less troublesome adverse effects - Depression - Hypotension - Sedation |
| Reserpine | Less troublesome adverse effects - Sedation - Severe psychiatric depression (high doses) - Hypotension |
| Diazepam (Valium) | - hallucinations - delusions - frequent falls |

3.5 – Multiple Sclerosis (MS)

- MS is a chronic autoimmune disorder that affects the CNS
- It is characterized by inflammation, damage to the myelin sheaths, and disruption of nerve impulses. This results in a wide range of symptoms, including fatigue, muscle weakness, numbness, and coordination problems.
- The disease can either have a relapsing or progressive development.

| | Mechanism | Clinical |
|----------------------------------|--|--|
| Dalfampridine | Block potassium channels → enhanced conduction in damaged nerves. | Improve walking |
| Fingolimod | ↓ the number of lymphocytes circulating in PNS and CNS, by binding the sphingosine 1-phosphate S1P receptor. | ↓ rate of relapses and slow progression of disease. |
| Interferon beta (β)-1b | ↓ the immune response that is directed against myelin. | ↓ frequency of relapses + ↓ number of new lesions |
| Prednisone | Corticosteroids used to relieve inflammation. | ↓ duration of relapse + ↓ MS flare symptoms. |
| Teriflunomide¹ | ↓ formation of overactive immune cells → ↓ inflammation and ↓ damage to CNS nerves. | ↓ rate of relapses and slow progression of disease. |
| Dimethyl fumarate | Activate the nuclear factor (erythroid-derived)-like-2 (NFR-2) transcriptional pathway. | ↓ stress, demyelination and nerve cell inflammation. |

¹ risk of hepatic toxicity

3.6 – Amyotrophic Lateral Sclerosis (ALS)


- ALS = Lou Gehrig disease
- Progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, causing weakness, muscle wasting and lead to respiratory failure.
- Cause/etiology unknown.
- Current treatment is mostly symptomatic.

3.6.1 – Gabapentin

| | Mechanism | Clinical | Toxicities |
|-----------------------------------|---|--|--|
| Gabapentin (antiepileptic) | Structural analog of GABA, does not activate GABA receptors directly. | Slow muscle strength decline + Nerve pain | - Dizziness - Sedation - Ataxia - Nystagmus |

3.6.2 – Riluzole


- Riluzole is the only drug that is specifically approved for ALS.



3.7 – Antispastic Drugs

- Antispastic drugs/muscle relaxants treat abnormally, severe, elevated skeletal muscle tone, spasms, caused by neurologic disease or injury.


3.7.1 – Treatment of Acute Spasticity



¹ not effective in muscle spasm resulting from CNS diseases

² these drugs are only used in short-term treatment.

3.7.2 – Treatment of Chronic Spasticity



¹ due to e.g. MS

CLINICAL CORRELATION

Malignant hyperthermia

- This emergency can be triggered by general anesthesia protocols (succinylcholine or tubocurarine).
- This is a severe condition including rapid temperature rise, muscle stiffness, tachycardia, tachypnea, sweating and altered mental status.
- It is characterized by a **massive release of calcium** from the sarcoplasmic reticulum of skeletal muscles.
- **Dantrolene** is given to block calcium release.

3.7.3 – Other Antispastic Drugs

| | Mechanism | Clinical | Toxicities |
|----------------------------------|---|--|---|
| Botulinum toxin A (BOTOX) | Produced by Clostridium Botulinum Block release of Ach -> inhibits neuromuscular transmission. | - Urinary incontinence - Reduce pain caused by severe spasm - Treat localized spasm (e.g. of eyes or face) - Parkinson disease symptoms - Cosmetic: reduce facial wrinkles | - Dry mouth - Dysphagia - Paralysis |

3.8 – Test Yourself: Neurodegenerative Diseases

1) Match the drug with the correct mechanism of increasing dopamine levels:

- | | |
|---------------|--|
| 1) Selegiline | a) Increase dopamine synthesis |
| 2) Levodopa | b) Increase amount of levodopa that enters the brain |
| 3) Carbidopa | c) Increase dopamine release from neurons |
| 4) Amantadine | d) Inhibit dopamine breakdown |

2) Why are dopamine receptor agonists (e.g. apomorphine) useful in advanced cases of Parkinson's?

- a) They provide immediate relief from symptoms.
- b) They do not need a functional dopaminergic neuron to produce an effect.
- c) They slow down progression by protecting dopaminergic neurons from further damage.
- d) They never cause side effects.

3) Which dopamine receptor agonists are D₂ and D₃ receptor agonists?

- a) Pramipexole and Rotigotine
- b) Rotigotine and Ropinirole
- c) Bromocriptine and Pramipexole
- d) Bromocriptine only

4) Which toxicity is seen only in rivastigmine, not the other central acetylcholinesterase inhibitors?

- a) bradycardia
- b) nausea + vomiting
- c) GI bleeding
- d) weight loss + anorexia

5) Fill in the blanks in the information about Huntington Disease:

- An autosomal dominant disorder with involuntary “dancing” movements (_____) and often psychosis or dementia.
- The GABA function in the brain is _____ and the dopaminergic functions _____.

6) Which of the MS drugs have a risk of hepatic toxicity

- a) Prednisone
- b) Fingolimod
- c) Teriflunomide
- d) Interferon beta-1b

7) Fill in the blanks:

| | Clinical |
|----------------------------|--|
| Dalfampridine | _____ |
| | ↓ rate of relapses and slow progression of disease. |
| Interferon beta (β)-1b | ↓ frequency of relapses + ↓ number of new lesions |
| | ↓ duration of relapse + ↓ MS flare symptoms. |
| Teriflunomide ¹ | ↓ _____ and slow progression of disease. |
| Dimethyl fumarate | ↓ stress, demyelination and nerve cell inflammation. |

8) Which drug is the only drug that is specifically approved for treating ALS (Lou Gehrig disease)?

9) Which drug treats chronic spasticity?

- a) Cyclobenzaprine
- b) Baclofen
- c) Orphenadrine
- d) Methocarbamol


Section 4 – Drugs for Abuse

- 4.1 – Central Nervous System Depressants
- 4.2 – Central Nervous System Stimulants
- 4.3 – Other Psychoactive Drugs
- 4.4 – Drugs for Treating Drug Dependence
- 4.5 – Test Yourself

4.1 – Central Nervous System Depressants


4.1.1 – Alcohols and Glycols

I. Effects



II. Methanol toxicity

- Methanol is a toxic form of alcohol; it can lead to optic nerve damage and anion gap metabolic acidosis.
- Methanol toxicity is treated with ethanol. Ethanol has a greater affinity for alcohol dehydrogenase and will more easily saturate it, this prevents the formation of formaldehyde and formate from methanol.




4.1.2 – Barbiturates and Benzodiazepines

- Sedative-hypnotic agents to treat anxiety disorders, insomnia, and other conditions.
- Long-term use leads to dependence.
- Withdrawal symptoms are similar to alcohol withdrawal.

| | Flunitrazepam ("roofies"/Rohypnol) | Pentobarbital | Gamma-hydroxybutyrate (GHB) |
|-------------------|--|---|---|
| GABA receptor | GABA _A (benzodiazepam) | GABA _A (barbiturate) | GABA _B |
| Taste? | No | Bitter | Salty |
| Clinical | Drowsiness, anterograde amnesia, impaired motor skills | Induce sleep, cause sedation | CNS depressant |
| "Date rape" drug? | Yes | No | Yes |
| Risk | Addiction, cognitive decline | Respiratory and cardiovascular depression | Death due do CNS depression when mixed with alcohol |

4.1.3 – Opioids




4.2 – Central Nervous System Stimulants

- Increase concentration of norepinephrine and dopamine in dopaminergic synapses. Mimic effects of the sympathetic nervous system.

4.2.1 – Amphetamine and its derivatives

I. Mechanism




II. Clinical aspect

| | Clinical | Drug abuse |
|---|---|--|
| Amphetamine | Medical indications for ADHD, obesity, narcolepsy and other sleep disorders. No specific antidote. | - Central and peripheral effects, e.g. euphoria - Sympathomimetic effects |
| Metamphetamine | | <i>Crystal meth:</i> - Euphoria - Cheap - Easy production |
| 3,4-methylene-dioxy-methamphetamine (MDMA) | PTSD + other mental health conditions | - Euphoria - Hallucinogenic properties - Sexual enhancer |

4.2.2 – Other stimulants

| | Clinical | Drug abuse | Toxicities |
|-----------------|--|--|---|
| Cocaine | Psychostimulant Local anesthetic | - Euphoria - Self-confidence - Mental alertness | - Alter tactile sensations - Cheyne-Stokes respiration - Cardiovascular, pulmonary, and neural toxicity |
| Nicotine | Treating dependence | - Mild euphoria ++ - Pharmacokinetic tolerance | - Excessive CNS stimulation - Cardiac toxicity - Respiratory paralysis |
| Caffeine | IV to treat apnea in neonates Prevent fatigue | - Euphoria - Hallucinogenic properties - Sexual enhancer | - Cardiovascular, respiratory and neoplastic disease |



One can see that cocaine blocks dopamine reuptake transporters, resulting in dopamine and norepinephrine stimulating the dopamine receptors longer. Cocaine also increases the reuptake of dopamine and NE into the vesicles that are released into the synapse with dopamine receptors.

4.3 – Other Psychoactive Drugs

4.3.1 – Cannabis and its Derivatives

- THC (tetrahydrocannabinol) is the main psychoactive compound in cannabis, causing the “high” sensation. It binds to cannabinoid receptors in the brain and body, which affect mood, pain perception, and appetite.

| | Mechanism | Clinical | Toxicities |
|-------------------|--|--|---|
| Marijuana | THC regulate neurotransmitter release -> Modulate activity of acetylcholine, dopamine and serotonin | Headache, insomnia, chronic pain | - Drug dependence - Mild euphoria followed by a depressive phase - Impairment of judgement and reflexes |
| Dronabinol | | Treat nausea (cancer chemotherapy) | |
| Nabilone | | Stimulate appetite (AIDS or anorexic patients) | |


4.3.2 – Hallucinogens

- Hallucinogens are psychoactive drugs that can alter perception, mood, and consciousness, leading to hallucinations, distortions of reality, and changes in thought patterns.
- They primarily work by binding to serotonin receptors in the brain which leads to altered neurotransmitter activity and communication between neurons.

| | LSD (Lethargic acid diethylamide) | Mescaline Psilocybin | PCP (Phencyclidine) |
|----------------|--|---------------------------------|--------------------------------------|
| Hallucinations | Yes | Yes | Yes |
| Cause delirium | No | No | Yes |
| Origin | Synthetic | Cactus Mushroom | As an anaesthetic (later removed) |
| Administration | Oral | Oral | Usually inhaled |
| Duration | 12h | 6h | 3-48h |
| Mechanism | Not understood | Not understood | Block glutamate NMDA-receptors |

4.4 – Drugs for Treating Drug Dependence

- Drug dependence is diagnosed on a patient’s history, psychological assessment, physical examination findings, and laboratory findings.




¹ When mixed with ethanol causes unpleasant effects like nausea, palpitations, dyspnea (++)

² Especially treat heroin addiction

CLINICAL CORRELATION

Opioid Overdose and Naloxone

- If a patient in an opioid overdose experience respiratory failure or other life-threatening symptoms, **naloxone** should be administered (IV or intranasally).
- Naloxone is a competitive opioid antagonist and will displace the opioid from the receptors. This will quickly restore normal breathing and consciousness.




¹ May induce seizures

² Causes neuropsychiatric side effects

4.5 – Test yourself

1) Fill in the blanks:



2) Why is Flunitrazepam (“roofies”/Rohypnol) used as a “date rape drug”?

- a) causes memory loss and sedation
- b) causes euphoria, making victims susceptible to coercion
- c) tasteless and fast onset
- d) increases libido and lowers inhibition
- e) all of the above

3) What does THC stand for?

- a) Trihydrocannabinol
- b) Tetrahydrocannabidiol
- c) Terpenhydrocannabinol
- d) Tetrahydrocannabinol

4) How do hallucinogens work?

5) Which hallucinogen/s can cause delirium?

- a) LSD
- b) Mescaline
- c) Psilocybin
- d) PCP
- e) all of them

